top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Adverse drug event reporting [[electronic resource] ] : the roles of consumers and health-care professionals : workshop summary / / Jeffrey M. Drazen ... [et al], rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy ; Institute of Medicine of the National Academies
Adverse drug event reporting [[electronic resource] ] : the roles of consumers and health-care professionals : workshop summary / / Jeffrey M. Drazen ... [et al], rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy ; Institute of Medicine of the National Academies
Pubbl/distr/stampa Washington, D.C., : National Academies Press, c2007
Descrizione fisica 1 online resource (82 p.)
Disciplina 362.29
Altri autori (Persone) DrazenJeffrey M. <1946->
Soggetto topico Drugs - Side effects
Drug monitoring
Soggetto genere / forma Electronic books.
ISBN 1-280-84426-4
9786610844265
0-309-66330-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ""Front Matter""; ""Reviewers""; ""Contents""; ""Summary""; ""1 Introduction""; ""2 Current Adverse Event Reporting Systems""; ""3 Active Surveillance Systems""; ""4 Consumer Involvement in Reporting Adverse Events""; ""5 Drug-Drug Interactions""; ""6 Drug Labels""; ""References""; ""Appendixes""; ""A Workshop Agenda""; ""B Speaker Biographies""
Record Nr. UNINA-9910454633303321
Washington, D.C., : National Academies Press, c2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Adverse drug event reporting [[electronic resource] ] : the roles of consumers and health-care professionals : workshop summary / / Jeffrey M. Drazen ... [et al], rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy ; Institute of Medicine of the National Academies
Adverse drug event reporting [[electronic resource] ] : the roles of consumers and health-care professionals : workshop summary / / Jeffrey M. Drazen ... [et al], rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy ; Institute of Medicine of the National Academies
Pubbl/distr/stampa Washington, D.C., : National Academies Press, c2007
Descrizione fisica 1 online resource (82 p.)
Disciplina 362.29
Altri autori (Persone) DrazenJeffrey M. <1946->
Soggetto topico Drugs - Side effects
Drug monitoring
ISBN 0-309-17979-3
1-280-84426-4
9786610844265
0-309-66330-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ""Front Matter""; ""Reviewers""; ""Contents""; ""Summary""; ""1 Introduction""; ""2 Current Adverse Event Reporting Systems""; ""3 Active Surveillance Systems""; ""4 Consumer Involvement in Reporting Adverse Events""; ""5 Drug-Drug Interactions""; ""6 Drug Labels""; ""References""; ""Appendixes""; ""A Workshop Agenda""; ""B Speaker Biographies""
Record Nr. UNINA-9910782032203321
Washington, D.C., : National Academies Press, c2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Adverse drug event reporting : the roles of consumers and health-care professionals : workshop summary / / Jeffrey M. Drazen ... [et al], rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy ; Institute of Medicine of the National Academies
Adverse drug event reporting : the roles of consumers and health-care professionals : workshop summary / / Jeffrey M. Drazen ... [et al], rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy ; Institute of Medicine of the National Academies
Edizione [1st ed.]
Pubbl/distr/stampa Washington, D.C., : National Academies Press, c2007
Descrizione fisica 1 online resource (82 p.)
Disciplina 362.29
Altri autori (Persone) DrazenJeffrey M. <1946->
Soggetto topico Drugs - Side effects
Drug monitoring
ISBN 0-309-17979-3
1-280-84426-4
9786610844265
0-309-66330-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ""Front Matter""; ""Reviewers""; ""Contents""; ""Summary""; ""1 Introduction""; ""2 Current Adverse Event Reporting Systems""; ""3 Active Surveillance Systems""; ""4 Consumer Involvement in Reporting Adverse Events""; ""5 Drug-Drug Interactions""; ""6 Drug Labels""; ""References""; ""Appendixes""; ""A Workshop Agenda""; ""B Speaker Biographies""
Record Nr. UNINA-9910820009703321
Washington, D.C., : National Academies Press, c2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
ADVERSE DRUG INTERACTIONS : a handbook for prescribers
ADVERSE DRUG INTERACTIONS : a handbook for prescribers
Edizione [Second edition.]
Pubbl/distr/stampa [Place of publication not identified], : CRC Press, 2017
Descrizione fisica 1 online resource (1,214 pages)
Disciplina 615.7/045
Soggetto topico Drugs - Side effects
Drug interactions
ISBN 0-429-58633-7
0-429-16002-X
1-4822-3622-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Half Title -- Title Page -- Copyright Page -- Table of Contents -- Acknowledgments -- Abbreviations -- Preface -- Easy Reference Guide to Drugs -- Introduction -- Drug Metabolism and Elimination -- Individual Variability of Adverse Drug Interactions -- Pathological States That Are Associated with Increased Risk of Adverse Drug Interactions -- Special Populations at Higher Risk of Adverse Drug Interactions -- Specific Clinical Problems -- Editors -- Contributors -- Part 1: Drugs Acting on the Cardiovascular System -- Part 2: Drugs Acting on the Central Nervous System -- Part 3: Anticancer and Immunomodulating Drugs -- Part 4: Anticoagulants -- Part 5: Antidiabetic Drugs -- Part 6: Other Endocrine Drugs -- Part 7: Analgesics -- Part 8: Musculoskeletal Drugs -- Part 9: Anesthetic Drugs -- Part 10: Drugs to Treat Infections -- Part 11: Drugs Acting on the Gastrointestinal Tract -- Part 12: Respiratory Drugs -- Part 13: Metabolic Drugs -- Part 14: Obstetrics and Gynecology -- Part 15: Drugs Used to Treat the Urinary System -- Part 16: Drugs of Abuse -- Part 17: Miscellaneous -- Part 18: Over-the-Counter/Online Drugs and Remedies -- Appendix A: Factors Associated with Drug Effects -- Appendix B: Factors Associated with Interactions -- Appendix C: Foods Implicated in Potentially Severe Interactions -- Appendix D: Clinical Drug Development -- Appendix E: Assessments of Manifestations of DDIs -- Appendix F: Triptan Sensations -- Appendix G: Assessment of Severity of Liver Disease -- Appendix H: Prescribing Guidelines for Elderly Patients -- Appendix I: Factors Affecting Efficacy of Anti-Infective Agents -- Appendix J: Assessments of Obesity.
Record Nr. UNINA-9910154926203321
[Place of publication not identified], : CRC Press, 2017
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Adverse drug reaction bulletin
Adverse drug reaction bulletin
Pubbl/distr/stampa Durham, Eng., : Adverse Drug Reaction Research Unit
Disciplina 615.704
Soggetto topico Drugs - Side effects
Drug-Related Side Effects and Adverse Reactions
Médicaments - Effets secondaires
Soggetto genere / forma Periodical
periodicals.
Periodicals.
Périodiques.
ISSN 2159-7774
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNINA-9910763988003321
Durham, Eng., : Adverse Drug Reaction Research Unit
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Adverse drug reactions / / edited by Anne Lee
Adverse drug reactions / / edited by Anne Lee
Edizione [2nd ed.]
Pubbl/distr/stampa London ; ; Chicago : , : Pharmaceutical Press, , 2006
Descrizione fisica 1 online resource (xxi, 474 p. )
Disciplina 615/.7042
Soggetto topico Drugs - Side effects
ISBN 0-85711-113-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Prelims -- Contents -- Preface -- Acknowledgements -- About the editor -- Contributors -- Chapter 1 - Introduction -- Epidemiology -- Classification and mechanisms -- Susceptibility -- Detection and diagnosis -- Healthcare professionals and adverse drug reactions -- References -- Further reading -- Chapter 2 - Side effects and patients -- Introduction -- Desire for information about side effects -- General perceptions -- Side effects and compliance -- Mandatory patient information leaflets -- Format of side-effect data for patients -- Key effects to consider when presenting side-effect data -- Patient reporting of ADRs -- The way forward -- References -- Further reading -- Chapter 3 - Pharmacogenetics and adverse drug reactions -- Introduction -- Adverse drug reactions -- Drug action -- Genetics revisited -- Genetic polymorphism and drug transporters -- Genetically determined pharmacodynamic variations -- Human leukocyte antigens and adverse drug reactions -- Utility of pharmacogenetics in the clinical setting -- References -- Further reading -- Glossary -- Chapter 4 - Adverse drug reactions in pregnancy -- Introduction -- Prescribing in pregnancy -- Drugs used to treat selected cardiovascular system disorders -- Drugs used to treat epilepsy -- Mental health disorders -- Drugs used in endocrine disorders -- Drugs used to treat infections -- Miscellaneous agents -- Summary -- References -- Further reading -- Glossary -- Chapter 5 - Drug-induced skin reactions -- Introduction -- Classification and mechanism -- Diagnosis -- Management points -- Exanthematous (erythematous) reactions -- Fixed drug eruption -- Urticaria and angio-oedema -- Acne -- Psoriasis and psoriasiform eruptions -- Purpura -- Vasculitis -- Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis -- Blistering drug eruptions -- Photosensitivity.
Lichenoid drug eruptions -- Pigmentary disorders -- Alopecia -- Hair gain -- Nail disorders -- References -- Further reading -- Chapter 6 - Gastrointestinal disorders -- Introduction -- The mouth -- The oesophagus -- Nausea and vomiting -- Stomach and duodenum -- Small intestine -- Colon -- Constipation -- Pancreatitis -- References -- Further reading -- Chapter 7 - Hepatic disorders -- Introduction -- Classification and mechanisms -- Signs and symptoms of liver disorders -- Risk factors -- Diagnosis of drug-induced liver damage -- Types of drug-induced liver disease -- Management of patients with drug-induced hepatic disease -- Prevention of drug-induced hepatic damage -- References -- Further reading -- Chapter 8 - Renal disorders -- Introduction -- Risk factors -- Diagnosis of drug-induced renal dysfunction -- Acute renal failure -- Chronic renal failure -- Nephrogenic diabetes insipidus -- Haemolytic uraemic syndrome -- Osmotic nephrosis -- Conclusion -- References -- Further reading -- Chapter 9 - Endocrine and metabolic disorders -- Introduction -- Drugs affecting thyroid function -- Medicines that may interfere with thyroid function tests -- Drugs affecting adrenal function -- Aldosterone synthesis -- Drugs affecting gonadotrophin release and gonadal function -- Hyperprolactinaemia -- Syndrome of inappropriate secretion of antidiuretic hormone -- Hyperglycaemia and diabetes -- Hypoglycaemia -- Disorders of fat metabolism -- References -- Further reading -- Chapter 10 - Respiratory disorders -- Introduction -- Nasal congestion -- Airway obstruction -- Parenchymal lung disorders -- Pulmonary oedema -- Pulmonary thromboembolism -- References -- Further reading -- Chapter 11 - Musculoskeletal disorders -- Introduction -- Muscle disorders -- Bone -- Joints -- Connective tissue -- References -- Further reading -- Chapter 12 - Blood disorders.
Introduction -- Aplastic anaemia -- Agranulocytosis -- Thrombocytopenia -- Pure red cell aplasia -- Haemolytic anaemia -- Megaloblastic anaemia -- References -- Further reading -- Chapter 13 - Mental health disorders -- Introduction -- Depression -- Psychosis -- Mania -- Behavioural toxicity -- Cognitive impairment -- Psychiatric manifestations of drug withdrawal reactions -- Use of SSRIs and venlafaxine in children and adolescents with major depressive disorder (MDD) -- Serotonin syndrome and neuroleptic malignant syndrome -- Management of drug-induced psychiatric disturbances -- References -- Further reading -- Chapter 14 - Cardiovascular effects -- Introduction -- Disorders of cardiac rhythm -- Disorders of systemic blood pressure -- Congestive heart failure -- Myocardial toxicity -- Pulmonary hypertension -- Stroke and heart attack risk -- References -- Further reading -- Chapter 15 - Neurological disorders -- Introduction -- Headache -- Effects on the neuromuscular junction and myasthenia gravis -- Seizures -- Coma and encephalopathy -- Neuropathies -- Guillain-Barré syndrome -- Drug-induced movement disorders -- Sudden sleep onset with dopaminergic drugs -- References -- Chapter 16 - Sexual dysfunction and infertility -- Introduction -- Infertility -- Sexual dysfunction -- References -- Further reading -- Index.
Record Nr. UNINA-9910164945803321
London ; ; Chicago : , : Pharmaceutical Press, , 2006
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
Pubbl/distr/stampa Weinheim, : Wiley-VCH
Descrizione fisica 1 online resource (506 p.)
Disciplina 615.704
Altri autori (Persone) VazRoy J
KlabundeThomas
Collana Methods and principles in medicinal chemistry
Soggetto topico Drugs - Side effects
Drugs - Side effects - Prevention
Drug interactions
Drug development
Drugs - Structure-activity relationships
Soggetto genere / forma Electronic books.
ISBN 1-282-78430-7
9786612784309
3-527-62147-4
3-527-62146-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction
2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates
2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity
2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation
3.5.1 Regulatory Guidance Documents
Record Nr. UNINA-9910145982103321
Weinheim, : Wiley-VCH
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
Pubbl/distr/stampa Weinheim, : Wiley-VCH
Descrizione fisica 1 online resource (506 p.)
Disciplina 615.704
Altri autori (Persone) VazRoy J
KlabundeThomas
Collana Methods and principles in medicinal chemistry
Soggetto topico Drugs - Side effects
Drugs - Side effects - Prevention
Drug interactions
Drug development
Drugs - Structure-activity relationships
ISBN 1-282-78430-7
9786612784309
3-527-62147-4
3-527-62146-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction
2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates
2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity
2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation
3.5.1 Regulatory Guidance Documents
Record Nr. UNINA-9910830632603321
Weinheim, : Wiley-VCH
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antitargets : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
Antitargets : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
Pubbl/distr/stampa Weinheim, : Wiley-VCH
Descrizione fisica 1 online resource (506 p.)
Disciplina 615.704
Altri autori (Persone) VazRoy J
KlabundeThomas
Collana Methods and principles in medicinal chemistry
Soggetto topico Drugs - Side effects
Drugs - Side effects - Prevention
Drug interactions
Drug development
Drugs - Structure-activity relationships
ISBN 1-282-78430-7
9786612784309
3-527-62147-4
3-527-62146-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction
2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates
2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity
2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation
3.5.1 Regulatory Guidance Documents
Record Nr. UNINA-9910877316903321
Weinheim, : Wiley-VCH
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz
Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz
Pubbl/distr/stampa Weinheim, Germany : , : Wiley-VCH, , [2015]
Descrizione fisica 1 online resource (1266 p.)
Disciplina 615.19
Collana Methods and principles in medicinal chemistry
Soggetto topico Drugs - Side effects
Drugs - Side effects - Prevention
Drug interactions
Drug development
Drugs - Structure-activity relationships
Drug-Related Side Effects and Adverse Reactions
Protein Kinase Inhibitors - adverse effects
Pharmacovigilance
ISBN 3-527-67364-4
3-527-67366-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto section 1. General concept for target-based safety assessment -- section 2. Hepatic side effects -- section 3. Cardiovascular side effects -- section 4. Kinase antitargets -- section 5. Examples of clinical translation.
Record Nr. UNINA-9910132261703321
Weinheim, Germany : , : Wiley-VCH, , [2015]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui